Faculty at the Center for Transplantation Sciences, Massachusetts General Hospital, presented data at the 2022 American Transplant Congress about Tonix Pharmaceuticals’ (NASDAQ:TNXP) TNX-1500 product candidate in development for the prevention of organ transplant rejection.
The presentations include data demonstrating that TNX-1500 showed activity in preventing organ rejection and was well tolerated in non-human primates.
The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Blockade of CD40L with TNX-1500 monotherapy consistently and safely prevented pathologic allo-immunity in a non-human primate cardiac allograft model without clinical thrombosis.
“To date, there has not been a humanized anti-CD40L antibody that can effectively prevent transplant rejections with acceptable level of tolerability,” Seth Lederman, M.D. and CEO of Tonix, said in a statement.
TNX-1500 is a third generation anti-CD40L monoclonal antibody that has been designed by protein engineering to reduce the potential for thrombosis.
“The animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function,” Dr. Lederman said. “We believe TNX-1500 has the potential for treating and preventing organ transplant rejection.”